Business Of Biotech

We love to hear from our listeners. Send us a message. SPECIAL EDITION: BoB@JPM Elixirgen Therapeutics CEO Akihiro Ko joins the Business of Biotech for the final  episode in our special series recorded at JPM Week in San Francico. Life Science Leader Chief Editor Ben Comer joined us for the conversation. We dive deep into Elixirgen's unique, temperature-controlled in-vivo gene expression tech...

We love to hear from our listeners. Send us a message. SPECIAL EDITION: BOB@JPM Flagship Pioneering plucked Michael Severino, M.D. away from AbbVie to run point at Tessera, a startup it's backed to pioneer a new category of genetic medicine it calls gene writing. The Business of Biotech caught up with Severino at the JP Morgan Healthcare Conference in San Francisco last month. We learned what...

We love to hear from our listeners. Send us a message. SPECIAL EDITION: BOB@JPM Bolt Biotherapeutics CEO Randall Schatzman, Ph. D. and CMO Edith Perez, M.D. are no strangers to the Business of Biotech, having previously joined us on episodes 14 and 18, respectively. The last time we spoke with Dr. Schatzman, he was preparing the company for its initial public offering. We caught up with him and Dr...

We love to hear from our listeners. Send us a message. SPECIAL EDITION: BoB@JPM The JP Morgan Healthcare Conference is a target-rich environment for conversations with the leaders of up-and-coming biopharma companies, so we took the Business of Biotech on the road. On today's episode, we sat down with Matt Coffey, Ph. D., who earned his Ph. D. in 1998 and turned his doctoral thesis into a bio...

We love to hear from our listeners. Send us a message. SPECIAL EDITION: BoB@JPM The Business of Biotech podcast took to the streets of San Francisco during the 41st Annual J.P. Morgan Healthcare Conference. This week's episode features a conversation with Sangamo Therapeutics CEO Sandy Macrae, Ph. D., who rationalizes the company's aggressive pipeline development and its decision to inve...

We love to hear from our listeners. Send us a message. Is it past time for a new approach to the COVID vaccine? Ocugen Chairman of the Board, Founder & CEO Shankar Musunuri, Ph. D. says yes, and his ideals would mark significant improvements: fewer shots, better durability, less post-vaccination transmission, and safety proven by time-tested technology. How would such a vaccine be produced? Dr...

We love to hear from our listeners. Send us a message. Call it fortuitous, good planning, instinct, or a combination of all three, but Nadim Ahmed's educational foundation— earned before the IT/Biology combination was cool— is serving him well as CEO at Cullinan Oncology. On this episode of the Business of Biotech, Ahmed shares his story and that of Cullinan Oncology's drug discovery eff...

We love to hear from our listeners. Send us a message. After more than 21 years leading process, product, and technical development efforts at Merck and Takeda, Piper Trelstad, Ph. D. joined the Bill & Melinda Gates Medical Research Institute (MRI) in January, 2022. On this episode of the Business of Biotech, we'll dive into how the MRI, a full-fledged clinical-stage biopharmaceutical com...

We love to hear from our listeners. Send us a message. Gain Therapeutics' newly-appointed CEO Matthias Alder offers up a deep, yet abundantly clear explanation of how his company is applying compute power to speed up  drug discovery.  At Gain, computational models help researchers winnow down not just which molecules might have therapeutic effect, but also how adept those molecules will be at...

We love to hear from our listeners. Send us a message. Join Matt Pillar for a conversation with Carine Boustany, PharmD and SVP, US Research Site Head and Global Head of Immunology and Respiratory Diseases at Boehringer Ingelheim.  On this episode of the Business of Biotech,  we walk through the story leading up to the recent approval of spesolimab.  In September 2022, spesolimab was approved in t...

We love to hear from our listeners. Send us a message. Recursion's unique, technology-aided approach to drug discovery has yielded one of the deepest, fastest-growing pipelines in emerging biotech.  It starts with a 20-petabyte-and-growing database designed to create comprehensive "maps of biology" that enable insight into the relationships between molecules and cell types. On this...

We love to hear from our listeners. Send us a message. Friend and frequent guest Allan Shaw rejoins the Business of Biotech to reflect on his recent presentation on innovative biotech financing at the BioFuture event in NYC. We also dig into  Bruce Booth's "Atlas Venture Year In Review ," revisiting and unpacking some quoteworthy material and metrics from both sources.  Allan offers...

We love to hear from our listeners. Send us a message. While many gene therapy development efforts focus on rare disease, Xalud Therapeutics is taking a swing that, measured in addressable patient market terms, is considerably bigger. Osteoarthritis, or OA, is a chronic, progressive joint disease that affects over 30 million people in the United States.  On this episode of the Business of Biotech,...

We love to hear from our listeners. Send us a message. In an industry that takes new business naming conventions to extremes, Abpro is a refreshingly clear exception. Brothers Ian Chan (CEO & Co-Founder) and Eugene Chan, M.D., (Chairman & Co-Founder) are antibody pros. The company's pipeline spans no fewer than 8 antibody candidates aimed at COVID-19, cancers including breast, gastric...

We love to hear from our listeners. Send us a message. 2023 is just around the corner, and it's shaping up to be a big year for Umoja Biopharma. The company is on the leading edge of the effort to break the solid tumor barrier with in vivo CAR T-cell therapies, with one such effort currently enrolling patients for a phase 1 trial. It's planning two more INDs in the coming year.  This epi...

We love to hear from our listeners. Send us a message. Nutcracker Therapeutics is a preclinical biopharma company developing  multimodal RNA-based therapeutics for HPV-driven tumors, T-cell lymphoma, and Genitourinary tumors. On this episode of the Business of Biotech, Chief Business Officer Geoff Nosrati, Ph. D. offers a comprehensive view of the RNA-based therapeutics landscape and sheds light o...

We love to hear from our listeners. Send us a message. Ticks are a scourge. They're vectors of multiple serious an debilitating diseases, and evolution has made them perfectly adept at attaching to their hosts—and potentially spreading those diseases virtually undetected— that ability owing to anti-inflammatory and anesthetic proteins in their saliva. But the emerging biotech Akari Therapeuti...

We love to hear from our listeners. Send us a message. Earlier this month, Surface Oncology shared that it will open a second stage of its monotherapy trial of SRF388, an antibody targeting IL-27, on the heels of a promising phase 2 data readout. Shortly before that release, the Business of Biotech caught up with Surface's CSO Vito Palombella, Ph. D. and CEO Rob Ross, M.D. in the company&apos...

We love to hear from our listeners. Send us a message. MIT-born startup Elicio Therapeutics' novel Amphiphile Technology Platform is designed to directly engage the lymphatic system in the deployment and delivery of therapeutic payloads. We caught up with Chief Scientific Officer Peter DeMuth, Ph. D.  at Elicio HQ in Boston to learn how the platform works, and how it's driving rapid clin...

We love to hear from our listeners. Send us a message. Anat Binur, Ph. D. is CEO and Co-Founder at Ukko, where she's leading an effort to   create new allergy therapeutics  by engineering the proteins that induce immune response in people who suffer from food allergies. The effort at Ukko is deeply rooted in computational biology. The company leverages artificial intelligence to analyze how t...

We love to hear from our listeners. Send us a message. In a particularly candid conversation, 4BIO Managing Partner Dmitry ‘Dima’ Kuzmin and Ray Therapeutics Co-Founder & CEO Paul Bresge share the recipe for a successful relationship between biotech VC firm and startup. Bresge offers insight into VC engagement strategy and pitch, Kuzmin dishes on what investors look for in terms of "funda...

We love to hear from our listeners. Send us a message. AbbVie  VP of Oncology Discovery Research Steve Davidsen, Ph. D.  is a living, breathing timeline of the company's cancer research and development efforts. He got his start with the company— Abbott at the time— way back in 1986. As such, he's charted the adoption of multiple advanced technologies that have contributed to the realizat...

We love to hear from our listeners. Send us a message. On this episode of The Business of Biotech, Obsidian Therapeutics CEO Paul Wotton, Ph. D. takes us behind the scenes to reveal what precipitated the FDA's clearance of its IND application for a novel, engineered tumor-infiltrating lymphocyte therapy called OBX-115.  Learn how the company navigated the regulatory path for a first-of-its-ki...

We love to hear from our listeners. Send us a message. Here's the story of BioStem, it's young founders, and how they reached commercial status in short order with a portfolio of proprietary regenerative wound care products developed from perinatal tissue.  Fueled by a personal story of resilience and inspiration, Jason Matuszewski (CEO) and Andrew VanVurst (COO) built a company that&apo...

We love to hear from our listeners. Send us a message. Using computational biology to hasten the effort, Omega Therapeutics' plan  is to "coopt nature's universal biological operating system for gene control and cell differentiation."  On this episode of the Business of Biotech, we dig into exactly what that means. We also explore the company's preclinical ambitions, which...